Bristol Myers, AbbVie drugs shake up first-line prescribing among gastroenterologists — report
Bristol Myers Squibb and AbbVie are changing up the inflammatory bowel disease (IBD) market with gastroenterologists, thanks to newer-to-market drugs
Bristol Myers Squibb and AbbVie are changing up the inflammatory bowel disease (IBD) market with gastroenterologists, thanks to newer-to-market drugs
Nearly 25 years ago, Spherix Global Insights’ CEO, Jennifer Robinson, and Cheeriodicals’ CEO, Gary Parisher, met when they entered the
With one of the most promising autoimmune and rare disease product pipelines in the industry, it is no surprise that Horizon
Takeda’s Entyvio, Janssen’s Stelara, and AbbVie’s Humira leave the most on the table when first-line biologic or small molecule agents
A high percentage of GA patients are either being seen for the first time, or not returning for follow-up visits
Despite highly favorable perceptions of the first approved treatment, dermatologists’ desire increased support from Eli Lilly sales representatives EXTON, Pa.,
The Philadelphia100® Forum and the Philadelphia Business Journal recognize Spherix Global Insights among this year’s top companies in the Greater
The World Health Organization (WHO) estimates that at least 2.2 billion people globally have a near or distance vision impairment.
Referrals from primary care physicians to rheumatologists are being delayed due to several factors EXTON, Pa., November 10, 2022 /PRNewswire/
While Eylea holds the second-place position, newcomer Vabysmo (Genentech) has already captured a small piece of the market and is
Expanded systemic lupus erythematosus (SLE) research in Europe reveals UK physicians perceive a higher unmet need and difficulty in treating
Independently funded research on the role of primary care physicians in CKD care, SGLT2 inhibitors and advancing care for IgA